Will FDA Approval of an In-House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative? [Yahoo! Finance]
Amphastar Pharmaceuticals, Inc. (AMPH)
Last amphastar pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amphastar.com/investor-relations
Company Research
Source: Yahoo! Finance
prefilled pen, deemed bioequivalent and therapeutically equivalent to Eli Lilly's FORTEO, with plans to launch the product in the US$585.0 million U.S. market by late 2025. A distinctive aspect of this approval is that Amphastar will manufacture the teriparatide product entirely in-house at its U.S. facility, which could reinforce supply reliability and support its focus on domestically produced injectables. We'll now examine how FDA approval of an in-house manufactured teriparatide pen could reshape Amphastar's investment narrative and risk profile. Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave To own Amphastar, you generally need to believe in its shift toward higher value injectables, supported by U.S. manufacturing and a growing pipeline, despite recent earnings pressure and underperformance versus the sector. The FDA approval of its in-house teriparatide pen directly supports this thesis, but the key near term catalys
Show less
Read more
Impact Snapshot
Event Time:
AMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPH alerts
High impacting Amphastar Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPH
News
- Amphastar: Baqsimi Props Up Flat Growth, But 2026 Guidance Looks Fragile [Seeking Alpha]Seeking Alpha
- 2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by analysts at Barclays PLC to a "hold" rating.MarketBeat
- Amphastar Pharmaceuticals (NASDAQ:AMPH) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $30.00 price target on the stock.MarketBeat
- Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why [Yahoo! Finance]Yahoo! Finance
AMPH
Earnings
- 11/6/25 - Beat
AMPH
Sec Filings
- 12/15/25 - Form 4
- 12/11/25 - Form 144
- 12/10/25 - Form 144
- AMPH's page on the SEC website